

The HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium



© Gates Archive/Ricci Shryock

The HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium, funded by the Bill & Melinda Gates Foundation, is a visionary project designed to accelerate HPV vaccination in low- and middle- income countries (LMICs). We harness collective expertise in policy, access, introduction, implementation, evaluation, and learning. Our overarching aim is to promote equity, program quality, and the rapid expansion of HPV vaccination among girls.

At the global level, our partners include the Bill & Melinda Gates Foundation (BMGF) and global vaccine partners (Gavi, WHO, UNICEF, and CDC), as well as the broader global health community, including HPV advocates/advocacy groups.

At the country level, we engage with EPI/MOH, local civil society organizations (CSOs)/NGOs, professional societies, women's groups, national cancer programs, and other country-level decision-makers, such as the Ministry of Education. The HAPPI Consortium, in collaboration with our esteemed partners, is managed by JSI together with Clinton Health Access Initiative (CHAI), the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, Jhpiego, and PATH.

The consortium implements targeted technical assistance for accelerated HPV vaccine introduction, stakeholder engagement and evidence-based decision-making, and coverage improvement. We also focus on accelerating learning from existing programs and implementation, with a strong commitment to translating lessons learned into policy, guidelines, and practices. Our role extends to complementing global coordination efforts among core HPV vaccine partners.

Our consortium is poised to deliver substantial benefits and impact to accelerate HPV vaccination among girls through:

- Targeted technical assistance to countries for accelerated HPV vaccine introduction, stakeholder engagement and evidence-based decision-making, and coverage improvement
- Targeted learning, measurement, and evaluation of existing programs and implementation
- Translation of lessons learned into policy, guidelines, and practices
- Extend and complement global coordination of the core HPV vaccine partners

About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries (LMIC) where access to prevention, screening, and treatment is limited. The HPV vaccine is one of the most effective tools in preventing cervical cancer and other HPV-related diseases[1]. However, there remains a critical need to improve vaccine access, especially for girls in LMICs. HAPPI combines expertise in policy,

access, introduction, implementation, and evaluation and learning to expedite HPV vaccine uptake and use. Our proactive approach involves synthesizing and disseminating evidence and best practices, working at a global level, alongside other HPV vaccine investments, to expand the availability and use of HPV vaccination evidence for improved program planning and implementation at all levels.



[1] World Health Organization. (2022, February 22). Cervical cancer [fact sheet](#).



@JSIhealth



@CHAI_health



@IVACTweets



@Jhpiego



@PATHtweets